*Department of Pathology;

†Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China; and

‡Department of Cardiology, The Lu'an Hospital Affiliated to Anhui Medical University, The Lu’ an People's Hospital, Lu'an, China.

Correspondence: Lihua Li, MMed, Department of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang, China (e-mail: [email protected]) or Jie Zhu, MMed, Department of Cardiology, The Lu'an Hospital Affiliated to Anhui Medical University, The Lu' an People's Hospital, Lu'an, China (e-mail: [email protected]).

Supported by the Scientific Research Fund of Anhui Medical University (2021xkj099) and the Jiangsu Provincial Health Commission Project (M2020016).

The authors report no conflicts of interest.

R. Liu drafted the manuscript. R. Liu, Z. Wang, L. Li, Y. Ji, and J. Zhu prepared the figures. Y. Ji, R. Liu, Z. Wang, L. Li, and J. Zhu edited and revised the manuscript. All the authors have read and approved the final version of the manuscript.

All relevant data are available in this article.

This review is based on the epigenetic modifications of acetylation and deacetylation and discusses the impact of related modifications on diabetes-related atherosclerosis. In this review, we first elaborate on the subdivision of the acetylation/deacetylase family and their impact on cardiovascular disease. This review also discusses the relationship between acetylation/deacetylation and the onset of diabetes and, based on the whole process of atherosclerosis, explored the impact of acetylation/deacetylation of diabetes on macrovascular complications. We also found that acetylation-related “metabolic memory” plays an important role in the development of diabetic atherosclerosis. In addition, we further discussed the impact of lifestyle on such diseases and proposed possible treatment options for related targets based on related animal experiments and clinical experiments.